-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TNM-001 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TNM-001 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TNM-001 in Respiratory Syncytial Virus (RSV) Infections Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IPH-6101 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IPH-6101 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IPH-6101 in Relapsed Acute Myeloid Leukemia Drug Details: IPH-6101 is...
-
Sector Analysis
Colorectal Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Colorectal Cancer Market Report Overview The colorectal cancer market sales across the 8MM were estimated at $15.8 billion in 2021. The market is expected to achieve a CAGR of more than 3% during 2021-2031. The global growth is driven by the anticipated approval and launch of 14 pipeline therapies and the label expansions of other agents. Colorectal cancer Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Colorectal cancer Market Forecast Download A Free Report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Solid Tumor Drug Details: Tipifarnib (Zarnestra) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TNM-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TNM-001 Drug Details TNM-001 is under development for the treatment of respiratory syncytial virus...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Respiratory syncytial virus (RSV) infection infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The Respiratory Syncytial Virus pipeline market research report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological...
-
Product Insights
Human Cytomegalovirus Envelope Glycoprotein B (gB) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Human Cytomegalovirus envelope glycoprotein B plays an important role in host cell entry and cell to cell virus transmission. It is involved in the initial attachment via binding to heparan sulfate together with the gM/gN complex that binds heparin with higher affinity. It interacts with host integrin ITGB1, PDGFRA and EGFR that likely serve as post attachment entry receptors. It participates in the fusion of viral and cellular membranes leading to virus entry into the host cell. The Human Cytomegalovirus...
-
Product Insights
Beta Nerve Growth Factor (Beta NGF or NGF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase-dependent proteolysis of platelet glycoprotein VI. The beta nerve growth factor drugs in development market report provides an in-depth analysis of Beta NGF or NGF targeted pipeline therapeutics. The report provides comprehensive information on the Beta Nerve Growth Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration...
-
Sector Analysis
Head and Neck Squamous Cell Carcinoma – Global Drug Forecast and Market Analysis to 2030
Head and neck squamous cell carcinoma (HNSCC) was the sixth most common cancer type by worldwide incidence in 2020. However, until recently, there had been limited research and development in HNSCC, resulting in a market with little competition and a stagnant pipeline. Historically, cytotoxic chemotherapies have made up the majority of the HNSCC market. There is currently little competition between targeted therapies in the HNSCC market, leaving an area of considerable opportunity for interested newcomers. Despite the approvals of PD-1...
-
Sector Analysis
Small Cell Lung Cancer – Opportunity Analysis and Forecasts to 2029
The small cell lung cancer (SCLC) market has experienced moderate growth since 2016, and is expected to increase further, from $698m in 2019 to $2.4bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate of 12.9%. Growth will be driven by the anticipated launch of 10 pipeline agents and greater market access across the 8MM for premium priced agents. This report notes that the main barriers for market growth include the absence of predictive biomarkers...